Literature DB >> 25442277

Determination of pharmacological interactions of uliginosin B, a natural phloroglucinol derivative, with amitriptyline, clonidine and morphine by isobolographic analysis.

Eveline D Stolz1, Liz G Müller1, Camila B Antonio1, Paola F da Costa1, Gilsane L von Poser1, François Noël2, Stela M K Rates3.   

Abstract

Uliginosin B is a natural phloroglucinol derivative, obtained from Hypericum species native to South America. Previous studies have shown that uliginosin B presents antidepressant-like and antinociceptive effects. Although its mechanism of action is still not completely elucidated, it is known that it involves the activation of monoaminergic neurotransmission. The aim of the current study was to further investigate the antinociceptive mechanism of action of uliginosin B by combining it with different drugs used for treating pain in clinical practice. The intraperitoneal administration of uliginosin B, morphine, amitriptyline and clonidine, alone or in mixture, produced a dose-dependent antinociceptive effect in the hot-plate assay in mice. The effect of the mixtures of drugs was studied using an adapted isobologram analysis at the effect level of 50% of the maximal effect observed. The analysis showed that the interactions between uliginosin B and morphine was synergistic, while the interactions between uliginosin B and amitriptyline or clonidine were additive. These findings point to uliginosin B as a potential adjuvant for pain pharmacotherapy, especially for opioid analgesia.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Analgesia adjuvant; Curved isobologram; Morphine synergism; Phloroglucinol derivative; Uliginosin B

Mesh:

Substances:

Year:  2014        PMID: 25442277     DOI: 10.1016/j.phymed.2014.08.009

Source DB:  PubMed          Journal:  Phytomedicine        ISSN: 0944-7113            Impact factor:   5.340


  1 in total

1.  Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System.

Authors:  Eveline Dischkaln Stolz; Paola Fontoura da Costa; Liciane Fernandes Medeiros; Andressa Souza; Ana Maria Oliveira Battastini; Gilsane Lino von Poser; Carla Bonan; Iraci L S Torres; Stela Maris Kuze Rates
Journal:  Evid Based Complement Alternat Med       Date:  2016-03-21       Impact factor: 2.629

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.